Improvement of Arterial Wall Lesions in Parallel with Decrease of Plasma Pentraxin-3 Levels in a Patient with Refractory Takayasu Arteritis After Treatment with Tocilizumab

Overview

Journal Case Rep Rheumatol

Publisher Wiley

Date 2017 Jul 6

PMID 28676840

Citations 2

Authors

Shiho Iwagaitsu

Taio Naniwa

Affiliations

Soon will be listed here.

Abstract

A 19-year-old Japanese woman with active Takayasu arteritis despite multiple conventional immunosuppressive therapies with glucocorticoids in combination with intravenous cyclophosphamide, azathioprine, or infliximab with methotrexate and tacrolimus was successfully treated by switching from infliximab to intravenous tocilizumab. Worsening of claudication of the legs and elevated acute phase reactants, including plasma pentraxin-3 levels, were observed during combination therapy with infliximab. Computed tomography demonstrated increased wall thickening with contrast enhancement in the preexisting lesion of the descending aorta and the femoral arteries. After switching from infliximab to tocilizumab, plasma pentraxin-3 levels gradually decreased to the normal range in parallel with the improvement of claudication. Follow-up computed tomographic scans confirmed the marked improvement of these arterial lesions. Moreover, plasma pentraxin-3 level was increased in response to the worsening of claudication that occurred just after switching to a subcutaneous tocilizumab injection. Measurements of plasma pentraxin-3 might be useful for evaluation of the vascular wall inflammation and therapeutic efficacy even during biologic therapy targeting tumor necrosis factor and interleukin-6.

Citing Articles

Mechanism and biomarkers in aortitis--a review.

Benhuri B, ElJack A, Kahaleh B, Chakravarti R J Mol Med (Berl). 2019; 98(1):11-23.

PMID: 31664480 DOI: 10.1007/s00109-019-01838-1.

Can cardiovascular magnetic resonance prompt early cardiovascular/rheumatic treatment in autoimmune rheumatic diseases? Current practice and future perspectives.

Mavrogeni S, Sfikakis P, Dimitroulas T, Koutsogeorgopoulou L, Katsifis G, Markousis-Mavrogenis G Rheumatol Int. 2018; 38(6):949-958.

PMID: 29516170 DOI: 10.1007/s00296-018-4004-6.

References

Mekinian A, Comarmond C, Resche-Rigon M, Mirault T, Kahn J, Lambert M . Efficacy of Biological-Targeted Treatments in Takayasu Arteritis: Multicenter, Retrospective Study of 49 Patients. Circulation. 2015; 132(18):1693-700. DOI: 10.1161/CIRCULATIONAHA.114.014321. View

Ishihara T, Haraguchi G, Kamiishi T, Tezuka D, Inagaki H, Isobe M . Sensitive assessment of activity of Takayasu's arteritis by pentraxin3, a new biomarker. J Am Coll Cardiol. 2011; 57(16):1712-3. DOI: 10.1016/j.jacc.2010.10.058. View

Misra R, Danda D, Rajappa S, Ghosh A, Gupta R, Mahendranath K . Development and initial validation of the Indian Takayasu Clinical Activity Score (ITAS2010). Rheumatology (Oxford). 2013; 52(10):1795-801. DOI: 10.1093/rheumatology/ket128. View

Bredemeier M, Rocha C, Barbosa M, Pitrez E . One-year clinical and radiological evolution of a patient with refractory Takayasu's arteritis under treatment with tocilizumab. Clin Exp Rheumatol. 2012; 30(1 Suppl 70):S98-100. View

Park M, Lee S, Park Y, Lee S . Serum cytokine profiles and their correlations with disease activity in Takayasu's arteritis. Rheumatology (Oxford). 2005; 45(5):545-8. DOI: 10.1093/rheumatology/kei266. View

Alibaz-Oner F, Aksu K, Yentur S, Keser G, Saruhan-Direskeneli G, Direskeneli H . Plasma pentraxin-3 levels in patients with Takayasu's arteritis during routine follow-up. Clin Exp Rheumatol. 2016; 34(3 Suppl 97):S73-6. View

Dagna L, Salvo F, Tiraboschi M, Bozzolo E, Franchini S, Doglioni C . Pentraxin-3 as a marker of disease activity in Takayasu arteritis. Ann Intern Med. 2011; 155(7):425-33. DOI: 10.7326/0003-4819-155-7-201110040-00005. View

Bottazzi B, Doni A, Garlanda C, Mantovani A . An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu Rev Immunol. 2009; 28:157-83. DOI: 10.1146/annurev-immunol-030409-101305. View

Tombetti E, Franchini S, Papa M, Sabbadini M, Baldissera E . Treatment of refractory Takayasu arteritis with tocilizumab: 7 Italian patients from a single referral center. J Rheumatol. 2013; 40(12):2047-51. DOI: 10.3899/jrheum.130536. View

10.

Seko Y, Sato O, Takagi A, Tada Y, Matsuo H, Yagita H . Restricted usage of T-cell receptor Valpha-Vbeta genes in infiltrating cells in aortic tissue of patients with Takayasu's arteritis. Circulation. 1996; 93(10):1788-90. DOI: 10.1161/01.cir.93.10.1788. View

11.

Uchida Y, Matsukawa N, Oguri T, Sakurai K, Miura T, Iwagaitsu S . Reversible cerebral vasoconstriction syndrome in a patient with Takayasu's arteritis. Intern Med. 2011; 50(15):1611-4. DOI: 10.2169/internalmedicine.50.5185. View

12.

Keser G, Direskeneli H, Aksu K . Management of Takayasu arteritis: a systematic review. Rheumatology (Oxford). 2013; 53(5):793-801. DOI: 10.1093/rheumatology/ket320. View

13.

Yamasaki K, Kurimura M, Kasai T, Sagara M, Kodama T, Inoue K . Determination of physiological plasma pentraxin 3 (PTX3) levels in healthy populations. Clin Chem Lab Med. 2009; 47(4):471-7. DOI: 10.1515/CCLM.2009.110. View

14.

Marquez J, Flores D, Candia L, Espinoza L . Granulomatous vasculitis. Curr Rheumatol Rep. 2003; 5(2):128-35. DOI: 10.1007/s11926-003-0040-6. View

15.

Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T . Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008; 112(10):3959-64. DOI: 10.1182/blood-2008-05-155846. View

16.

Salvarani C, Magnani L, Catanoso M, Pipitone N, Versari A, Dardani L . Rescue treatment with tocilizumab for Takayasu arteritis resistant to TNF-α blockers. Clin Exp Rheumatol. 2012; 30(1 Suppl 70):S90-3. View

17.

Noris M, Daina E, Gamba S, Bonazzola S, Remuzzi G . Interleukin-6 and RANTES in Takayasu arteritis: a guide for therapeutic decisions?. Circulation. 1999; 100(1):55-60. DOI: 10.1161/01.cir.100.1.55. View

18.

Salvarani C, Cantini F, Boiardi L, Hunder G . Laboratory investigations useful in giant cell arteritis and Takayasu's arteritis. Clin Exp Rheumatol. 2004; 21(6 Suppl 32):S23-8. View